Digestive Tolerance of Slightly Hydrolyzed Starter Infant Formula With Probiotics
NCT ID: NCT01036243
Last Updated: 2012-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
480 participants
INTERVENTIONAL
2009-12-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Probiotic Formula and Infant Growth
NCT01476397
The Effects on Growth of a Non-Routine Infant Formula
NCT00655720
Gastrointestinal Tolerability of a Partially Hydrolyzed Ready-to-feed Infant Formula in Healthy Newborns
NCT05097924
Gastrointestinal Tolerance Evaluation of an Infant Formula
NCT03307122
Gastrointestinal Tolerance of Infant Formula
NCT02322138
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It has been reported that infants receiving a casein predominant formula had less unformed stools than those receiving a whey predominant formula. Hydrolysation of protein resulted in reduced gastro-intestinal transit time and some studies using extensively hydrolyzed protein formula have shown more liquid stools.
A reduction of crying hours was also described in infant receiving an hydrolyzed formula. Some probiotics were reported with potential benefit on the gut comfort.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test formula 1
Hydrolyzed formula with probiotics
test formula 1
hydrolyzed formula with probiotics
test formula 2
acidified hydrolyzed formula.
test formula 2
acidified hydrolyzed formula
Test formula 3
hydrolyzed formula without probiotics
test formula 3
hydrolyzed formula without probiotics
reference product
standard infant formula
reference formula
standard infant formula
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
test formula 1
hydrolyzed formula with probiotics
test formula 2
acidified hydrolyzed formula
test formula 3
hydrolyzed formula without probiotics
reference formula
standard infant formula
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Birth weight \< 2500g and \> 4500g
* Gestational age \< 37 weeks and \> 42 weeks
* Infants who cannot be breastfed because of the maternal status
* Willing to exclusively consume the assigned study formula with whey protein
* Are likely to be compliant
* Mother/caregiver demonstrates an understanding of the given information and ability to record the requested data
Exclusion Criteria
* Significant pre-natal and/or post-natal disease
* Receiving systemic antibiotic treatment at time of enrolment
* Infant with symptoms of allergy to cow's milk
* Infant's family cannot be expected to comply with treatment (feeding regimen)
* Subjects who cannot be expected to comply with treatment
* Currently participating or having participated in another clinical trial during the last month
11 Days
30 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Société des Produits Nestlé (SPN)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
A/Prof. Boosba Vivatvakin, MD
Role: PRINCIPAL_INVESTIGATOR
Pediatric Gastroenterology Unit,Faculty of Medicine, Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chulalongkorn University
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07.06 INF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.